Scilex Holding Company (SCLX)
NASDAQ: SCLX · Real-Time Price · USD
4.040
-0.350 (-7.97%)
At close: May 9, 2025, 4:00 PM
4.020
-0.020 (-0.50%)
After-hours: May 9, 2025, 4:31 PM EDT
Scilex Holding Company Employees
Scilex Holding Company had 115 employees as of December 31, 2024. The number of employees increased by 10 or 9.52% compared to the previous year.
Employees
115
Change (1Y)
10
Growth (1Y)
9.52%
Revenue / Employee
$492,087
Profits / Employee
-$633,104
Market Cap
20.99M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 115 | 10 | 9.52% |
| Dec 31, 2023 | 105 | 15 | 16.67% |
| Dec 31, 2022 | 90 | 14 | 18.42% |
| Dec 31, 2021 | 76 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SCLX News
- 8 days ago - Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL. - GlobeNewsWire
- 9 days ago - Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule - GlobeNewsWire
- 17 days ago - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025 - GlobeNewsWire
- 23 days ago - Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis - GlobeNewsWire
- 24 days ago - Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada - GlobeNewsWire
- 4 weeks ago - Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewsWire
- 6 weeks ago - Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva - GlobeNewsWire
- 2 months ago - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025 - GlobeNewsWire